Related Experiment Videos
Therapeutic options: Addressing the current dilemma.
1Department of Psychiatry and Alimentary Pharmabiotic Centre, University of Cork, Cork, Ireland. t.dinan@ucc.ie
Summary
Pharmacotherapy, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), is key for generalized anxiety disorder (GAD). New medications offer improved safety and tolerability for long-term GAD management.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Medicine
Background:
- Generalized anxiety disorder (GAD) management traditionally involves pharmacotherapy and psychotherapy.
- Anxiolytics and antidepressants have been historically used, with a recent shift towards SSRIs and SNRIs.
- Newer medications demonstrate comparable efficacy to older treatments with enhanced safety and tolerability profiles.
Purpose of the Study:
- To review current pharmacotherapeutic approaches for GAD.
- To highlight the evolution of GAD treatment strategies.
- To identify the need for improved GAD pharmacotherapies.
Main Methods:
- Literature review of pharmacotherapy in GAD management.
- Analysis of treatment trends, including SSRIs and SNRIs.
- Evaluation of drug efficacy, safety, and tolerability.
Main Results:
- SSRIs and SNRIs are increasingly preferred for GAD due to better safety and tolerability.
- Current treatments, while effective, necessitate long-term patient supervision.
- Existing pharmacotherapies may not fully meet the ideal treatment goals for GAD.
Conclusions:
- Pharmacotherapy remains central to symptomatic GAD management.
- There is an ongoing need for more effective, faster-acting, safer, and better-tolerated GAD treatments.
- Comprehensive GAD management requires sustained physician oversight and a focus on functional recovery.